Two Sigma Investments LP Lowers Stock Position in Stoke Therapeutics, Inc. (NASDAQ:STOK)

Two Sigma Investments LP decreased its holdings in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 53.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 53,950 shares of the company's stock after selling 62,728 shares during the quarter. Two Sigma Investments LP owned 0.10% of Stoke Therapeutics worth $595,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Bank of New York Mellon Corp increased its stake in shares of Stoke Therapeutics by 1.4% during the fourth quarter. Bank of New York Mellon Corp now owns 93,195 shares of the company's stock valued at $1,028,000 after buying an additional 1,330 shares during the period. Graham Capital Management L.P. increased its position in shares of Stoke Therapeutics by 8.5% during the fourth quarter. Graham Capital Management L.P. now owns 18,634 shares of the company's stock valued at $206,000 after acquiring an additional 1,453 shares in the last quarter. Gilder Gagnon Howe & Co. LLC raised its position in Stoke Therapeutics by 2.0% in the 4th quarter. Gilder Gagnon Howe & Co. LLC now owns 92,546 shares of the company's stock worth $1,021,000 after buying an additional 1,791 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in Stoke Therapeutics by 6.3% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 37,455 shares of the company's stock valued at $414,000 after buying an additional 2,215 shares during the last quarter. Finally, Rhumbline Advisers grew its stake in shares of Stoke Therapeutics by 6.0% during the 4th quarter. Rhumbline Advisers now owns 49,374 shares of the company's stock valued at $545,000 after purchasing an additional 2,787 shares during the period.

Insider Buying and Selling

In other news, Director Edward M. Md Kaye sold 10,382 shares of the business's stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $90,011.94. Following the sale, the director now owns 148,253 shares of the company's stock, valued at $1,285,353.51. The trade was a 6.54% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Barry Ticho sold 6,471 shares of Stoke Therapeutics stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $10.03, for a total value of $64,904.13. Following the transaction, the insider now directly owns 25,782 shares of the company's stock, valued at approximately $258,593.46. This represents a 20.06% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 24,748 shares of company stock worth $225,687 over the last 90 days. 11.30% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. Cantor Fitzgerald upgraded shares of Stoke Therapeutics to a "strong-buy" rating in a research report on Wednesday, May 14th. Chardan Capital reaffirmed a "buy" rating and set a $24.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, March 19th. HC Wainwright reduced their price objective on Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating on the stock in a research note on Wednesday, May 14th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $22.00 price target on shares of Stoke Therapeutics in a research note on Wednesday, April 9th. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Stoke Therapeutics has an average rating of "Buy" and an average target price of $23.20.

Stoke Therapeutics Stock Down 0.1%

Shares of NASDAQ STOK traded down $0.01 during midday trading on Monday, hitting $11.13. The stock had a trading volume of 452,056 shares, compared to its average volume of 704,340. The stock has a 50 day simple moving average of $8.77 and a 200-day simple moving average of $9.64. The company has a market capitalization of $607.66 million, a PE ratio of -5.30 and a beta of 1.09. Stoke Therapeutics, Inc. has a 1 year low of $5.35 and a 1 year high of $17.58.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last released its quarterly earnings results on Monday, March 24th. The company reported ($0.18) earnings per share for the quarter, topping analysts' consensus estimates of ($0.56) by $0.38. The business had revenue of $22.61 million during the quarter, compared to analysts' expectations of $4.20 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. As a group, analysts expect that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current fiscal year.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.